Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS

Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.